POSTERIOR PITUITARY EXTRACT is
known to lower the portal venous pressure in animalsl-3 and in man a similar effect has been demonstrated during the control of bleeding from esophageal varices with intravenous pitressin.44 It has been suggested that pitressin lowers portal pressure by increasing splanchnic resistance.7
The present communication concerns the effects of intravenous pitressin on splanchnic hemodynamics in control subjects and in patients with liver disease. The patients included some with cirrhosis in whom the portal vein was patent and some with a surgical portacaval anastomosis. Patients with normal liver structure but with occlusion of the portal vein were also studied. It was thus possible to study the effects of pitressin upon the splanchnic hemodynamics as a whole, and also upon the liver hemodynamics independent of the splanchnic bed in patients in whom portal venous blood was totally diverted from the liver.
Methods
The patients were divided into three groups. Group 1 consisted of four subjects without liver disease, group 2 consisted of 10 patients with portal cirrhosis in whom splenic venography had confirmed that the portal vein was patent. These patients had varying degrees of portal hypertension. Group 3 consisted of 11 patients with portal cirrhosis and a patent end-to-side portacaval anastomosis confirmed by splenic venography, and two patients in whom splenic venography showed a blocked portal vein and who had a normal liver biopsy.
Estimation of Hepatic Blood Flow
A size-9 radiopaque cardiac catheter was introduced into one of the main right hepatic veins under fluoroscopic control. The Twenty units of pitressin (Parke-Davis) (diluted in 100 ml. of 5 per cent dextrose) were infused intravenously over a 10-minute period. During the pitressin infusion and for a further 10 minutes after completion of the infusion, (0 to 20 minutes), no samples of blood were taken. After this time interval further paired samples of arterial and hepatic venous blood were obtained for BSP analysis at 10-minute intervals up to 60 minutes following the commencement of the pitressin infusion (20 to 60 minutes). In certain patients the sampling was extended to 100 minutes after Most patients experienced abdominal discomfort with cramp sensations and evacuation of the bowels during the pitressin infusion and also tightness of the skin with marked facial pallor. These side effects passed off rapidly and were not present during the measurements made in periods 2 and 3.
Discussion
The validity of the calculation of resistance in the splanchnic circulation is dependent upon several assumptions. The abrupt drop in pressure seen on withdrawing a catheter from the wedged hepatic position suggests that the site of resistance to hepatic venous *+ = One standard deviation.
outflow is located at the site of pressure drop. The wedged hepatic venous pressure is almost certainly a measure of hepatic sinusoidal pressure15 and its close agreement with the directly recorded portal venous pressure10 15-17 depends upon the free flow of portal blood from the portal vein to the hepatic sinusoids, through a low-resistance circuit. In the presence of obstruction to portal venous flow or surgical diversion of portal blood through a portacaval anastomosis, the wedged hepatic venous pressure is no longer related to the portal pressure1', 18 and reflects only the hepatic sinusoidal pressure. Hence the site of resistance to hepatic venous outflow may be located anywhere between the sinusoids and the main hepatic veins. The anatomic location of this resistance does not detract from the validity of calculating the resistance from the pressure gradient and the estimated hepatic blood flow. The gradient between the free hepatic vein pressure and the inferior vena caval pressure rarely exceeds 1 mm. Hg and so adds little to the postsinusoidal resistance. The calculation of splanchnic resistance is dependent upon the assumption that estimated hepatic blood flow equals splanchnic blood flow, and that the measured indirect portal pressure corresponds to the pressure on the venous side of the mesenteric vessels. In the absence of a portal collateral circulation, hepatic blood flow must equal splanchnic blood flow. If a portal collateral circulation exists as in the two patients in group 2, the calculated splanchnic resistance is overestimated. Nevertheless, the percentage changes induced by pitressin are probably valid measures of the changes in splanchnic resistance even if the absolute measurements are overestimated. In order to determine the best estimate of portal venous pressure, a mean of the intrasplenic and wedged hepatic venous pressures was used if both were available and the portal vein was unobstructed and in functional continuity with the liver.
The concept of hepatic arteriolar resistance was introduced to estimate the resistance to inflow of hepatic arterial blood to the liver in patients in whom portal venous blood was totally diverted from the liver. If the wedged hepatic venous pressure measures hepatie sinusoidal pressure, then this calculated resistance is valid. In these patients the inesenteric component of the splanchnic resistance could not be calculated as the blood flow in the portal vein was not measured, but, the pressure in the portal circuit was measured by splenic pressure recordings and changes in this pressure were interpreted as indexing changes in mesenteric arteriolar resistance.
The mechanism whereby pitressin lowers the portal pressure is related to the increase in calculated splanchnic resistance in patients with an intact portal vein. Im patients with total prehepatic deviation of portal blood the reduction in portal pressure (ISP) was of a similar degree to that observed in patients with a patent portal vein and suggests therefore that the mesenteric arteriolar resistance was increased as well as the hepatic arteriolar resistance in these patients. The similarity of response in patients with and without cirrhosis, suggests that pitressin affects the mesenteric arterioles of the cirrhotic and noncirrhotic patient to a similar degree. The elevated postsinusoidal resistfance in cirrhosis is probably only reduced with prolonged medical treatment and diuretic therapy in patients with ascites or fatty livers. 29 In these patients one may postulate a reduction in intrahepatic edema or fat as the mechlanism whereby the hepatic venous outflow obstruction is reduced. One may therefore conclude that pharmacologically induced reductions in the portal pressure may only be achieved by increasing the splanchnic resistance, and pitressin is the most potent splanchnic vasoconstrictor available.
Summary
The effects of 20 units of pitressin administered intravenously on the splanchnic circulation in four patients without liver disease, 10 patients with cirrhosis and a patent portal vein, 11 patients with cirrhosis and an end-to-side portacaval anastomosis and two patients with an extrahepatic portal vein obstruction and a normal liver structure, were observed. Estimated hepatic blood flow and wedged hepatic venous and intrasplenic pressures were measured in all groups, and the splanchnic, hepatic arteriolar, and hepatic postsinusoidal resistances were calculated. Pitressin reduced the portal pressure by an average of 39 per cent for 1 hour. Estimated hepatic blood flow was reduced by 40 per cent. Splanchnic resistance was increased by 87 per cent and hepatic arteriolar resistance by 77 per cent. Postsinusoidal resistance was not affected. The drop in portal pressure could be related to the increases in splanchnic resistance. There was no difference in the response to pitressin between patients with cirrhosis and patients with normal liver structure and function. It is suggested that the fundamental lesion causing portal hypertension in cirrhosis is an obstruction to the hepatic venous outflow and that mesenteric and hepatic arteriolar venous anastomoses are not operative in the genesis of portal hypertension in cirrhosis. This obstruction to hepatic venous outflow is not alterable pharmacologically and any attempts to lower portal pressure by medical means must be achieved by alterations in the splanchnic resistance. Pitressin appears to be the most potent splanchnic vasoconstrictor available.
